KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $12.1 million.

  • Nektar Therapeutics' Other Accumulated Expenses fell 3255.19% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 3255.19%. This contributed to the annual value of $14.5 million for FY2024, which is 4284.44% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Other Accumulated Expenses is $12.1 million, which was down 3255.19% from $15.4 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Other Accumulated Expenses high stood at $20.0 million for Q3 2021, and its period low was $6.9 million during Q3 2023.
  • Its 5-year average for Other Accumulated Expenses is $13.4 million, with a median of $14.5 million in 2024.
  • In the last 5 years, Nektar Therapeutics' Other Accumulated Expenses plummeted by 5472.59% in 2022 and then surged by 15785.84% in 2024.
  • Nektar Therapeutics' Other Accumulated Expenses (Quarter) stood at $15.5 million in 2021, then plummeted by 54.73% to $7.0 million in 2022, then surged by 44.48% to $10.1 million in 2023, then skyrocketed by 42.84% to $14.5 million in 2024, then decreased by 16.39% to $12.1 million in 2025.
  • Its Other Accumulated Expenses stands at $12.1 million for Q3 2025, versus $15.4 million for Q2 2025 and $11.8 million for Q1 2025.